clinical trial · NCT04321343
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
NASH - Nonalcoholic SteatohepatitisPXL065Placebo oral tablet
brief summary
This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment
started
Sep 1, 2020
primary completion
Jun 8, 2022
completion
Jun 20, 2022
last updated
Aug 29, 2023
detailed description
The study will be performed in patients with NASH. The primary endpoint will be the assessment of the change in the percentage of liver fat content (assessed by MRI-PDFF).
official title
A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol